个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共8条记录   Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581 [作者：Banham, AH; Pulford, K,期刊：Expert Opinion on Therapeutic Patents, 页码：1023-1028 , 文章类型： Article，,卷期：2009年19-7] Background: CD4(+)CD25(+) regulatory T cells (Tregs) regulate immunotolerance. Treg depletion causes autoimmune disease, whereas Treg expansion can prevent effective immunosurveillance of 'non-self' antigens in many clin... Selective MMP-12 inhibitors: WO-2008057254 [作者：Norman, P,期刊：Expert Opinion on Therapeutic Patents, 页码：1029-1034 , 文章类型： Article，,卷期：2009年19-7] Amino-substituted xanthene, thioxanthene and carbazole sulfonamido-carboxylic acid of carboxamido carboxylic acid derivatives, their use to treat metalloprotease mediated conditions, and especially to inhibit MMP-12, and... Humanized anti-EphB4 antibodies for the treatment of carcinomas and vasculogenesis-related diseases [作者：Xu, ZH; Jin, HJ; Qian, QJ,期刊：Expert Opinion on Therapeutic Patents, 页码：1035-1037 , 文章类型： Article，,卷期：2009年19-7] The invention provides human, humanized or chimeric versions of anti-EphB4 mouse monoclonal antibodies that bind to the human EphB4 receptor tyrosine kinase. The described anti-EphB4 antibodies are derived from two murin... Antibody-based immunotherapeutic attempts in experimental animal models of prion diseases [作者：Sakaguchi, S; Ishibashi, D; Matsuda, H,期刊：Expert Opinion on Therapeutic Patents, 页码：907-917 , 文章类型： Review，,卷期：2009年19-7] Background: There has been a dramatic decrease in the risk of transmission of bovine spongiform encephalopathy to humans. in contrast, the risk of human-to-human transmission of variant Creutzfeldt-Jakob disease (vCJD) v... Bradykinin receptor antagonists - a review of the patent literature 2005-2008 [作者：Fincham, CI; Bressan, A; Paris, M; Rossi, C; Fattori, D,期刊：Expert Opinion on Therapeutic Patents, 页码：919-941 , 文章类型： Review，,卷期：2009年19-7] Background: For > 20 years, pharmaceutical companies and academic centers have been developing bradykinin antagonists. The patent literature on these molecules (up to and including 2004) has been analyzed previously in t... Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007-2008 [作者：Corbett, JW,期刊：Expert Opinion on Therapeutic Patents, 页码：943-956 , 文章类型： Review，,卷期：2009年19-7] Background: Acetyl-CoA carboxylase (ACC) is a biologic target that is receiving increased attention for the treatment of obesity and type 2 diabetes mellitus. Inhibition of this enzyme, either in transgenic mice or pharm... Novel patent publications on high-affinity nicotinic acid receptor agonists [作者：Shen, HC; Colletti, SL,期刊：Expert Opinion on Therapeutic Patents, 页码：957-967 , 文章类型： Review，,卷期：2009年19-7] Background: Nicotinic acid (NA) has been used as a drug to treat dyslipidemia for > 50 years. In outcome clinical trials, NA displayed remarkable efficacy in patients with cardiovascular diseases by modifying lipid profi... Chemical penetration enhancers: a patent review [作者：Ahad, A; Aqil, M; Kohli, K; Chaudhary, H; Sultana, Y; Mujeeb, M; Talegaonkar, S,期刊：Expert Opinion on Therapeutic Patents, 页码：969-988 , 文章类型： Review，,卷期：2009年19-7] Background: Ever since transdermal drug delivery came into existence, it has offered great promises, although most of them are yet to be fulfilled owing to some intrinsic restrictions of the transdermal route. On the pos...